| Literature DB >> 32068257 |
José A Calvache1,2, Maira Vera-Montoya2, Darío Ordoñez2, Adrian V Hernandez3,4, Douglas Altman5, David Moher6.
Abstract
INTRODUCTION: Case reports represent a relevant, timely and important study design in advancing medical scientific knowledge. They allow integration between clinical practice and clinical epidemiology. We aimed to assess the completeness of reporting (COR) of case reports published in high-impact journals. We assessed the COR of case reports using the CARE guidelines.Entities:
Keywords: case report; editorial policies; guideline adherence; guidelines as topics; publishing/standards
Mesh:
Year: 2020 PMID: 32068257 PMCID: PMC7187208 DOI: 10.1111/eci.13215
Source DB: PubMed Journal: Eur J Clin Invest ISSN: 0014-2972 Impact factor: 4.686
CARE guideline 2016 checklist*
| Topic | Item | Question |
|---|---|---|
| Title | 1 | The words “case report” should be in the title along with what is of greatest interest in this case |
| Keywords | 2 | The key elements of this case in 2‐5 keywords |
| Abstract | 3a | Introduction—What is unique about this case? What does it add to the medical literature? |
| 3b | The main symptoms of the patient and the important clinical findings | |
| 3c | The main diagnoses, therapeutics interventions and outcomes | |
| 3d | Conclusion—What are the main “take‐away” lessons from this case? | |
| Introduction | 4 | Brief background summary of this case referencing the relevant medical literature |
| Patient Information | 5a | Demographic information (such as age, gender, ethnicity, occupation) |
| 5b | Main symptoms of the patient (his or her chief complaints) | |
| 5c | Medical, family and psychosocial history including co‐morbidities and relevant genetic information | |
| 5d | Relevant past interventions and their outcomes | |
| Clinical Findings | 6 | Describe the relevant physical examination (PE) findings |
| Timeline | 7 | Depict important milestones related to your diagnoses and interventions (table or figure) |
| Diagnostic Assessment | 8a | Diagnostic methods (such as PE, laboratory testing, imaging, questionnaires) |
| 8b | Diagnostic challenges (such as financial, language or cultural) | |
| 8c | Diagnostic reasoning including other diagnoses considered | |
| 8d | Prognostic characteristics (such as staging in oncology) where applicable | |
| Therapeutic Intervention | 9a | Types of intervention (such as pharmacologic, surgical, preventive, self‐care) |
| 9b | Administration of intervention (such as dosage, strength, duration) | |
| 9c | Changes in intervention (with rationale) | |
| Follow‐up and Outcomes | 10a | Clinician‐assessed outcomes and when appropriate patient‐assessed outcomes |
| 10b | Important follow‐up test results | |
| 10c | Intervention adherence and tolerability (How was this assessed?) | |
| 10d | Adverse and unanticipated events | |
| Discussion | 11a | Discussion of the strengths and limitations in the management of this case |
| 11b | Discussion of the relevant medical literature | |
| 11c | The rationale for conclusions (including assessment of possible causes) | |
| 11d | The main “take‐away” lessons of this case report | |
| Patient Perspective | 12 | Did the patient share his or her perspective or experience? (Include when appropriate) |
| Informed Consent | 13 | Did the patient give informed consent? Please provide if requested |
| Additional Information | 14 | Acknowledgement section; Competing Interests; IRB approval when required |
Source: http://www.care-statement.org/care-checklist.html.
Median completeness of reporting (COR) per topic and proportion of individual COR score of each question of the CARE statement in included case reports
| Topic | Item | Question | Median COR (%) | Proportion of individual COR (%) | Proportion of agreement (%) | Kappa coefficient |
|---|---|---|---|---|---|---|
| Title | 1 | The words “case report” should be in the title along with what is of greatest interest in this case | 21 | 21 | 93 | 0.757 |
| Keywords | 2 | The key elements of this case in 2‐5 key words | 2 | 2 | 98 |
|
| Abstract | 3a | Introduction—What is unique about this case? What does it add to the medical literature? | 59 | 55 | 64 | 0.231 |
| 3b | The main symptoms of the patient and the important clinical findings | 63 | 69 | 0.385 | ||
| 3c | The main diagnoses, therapeutics interventions, and outcomes | 66 | 76 | 0.523 | ||
| 3d | Conclusion—What are the main “take‐away” lessons from this case? | 54 | 56 | 0.000 | ||
| Introduction | 4 | Brief background summary of this case referencing the relevant medical literature | 71 | 71 | 79 | 0.560 |
| Patient Information | 5a | Demographic information (such as age, gender, ethnicity, occupation) | 93 | 76 | 79 | 0.534 |
| 5b | Main symptoms of the patient (his or her chief complaints) | 100 | 97 |
| ||
| 5c | Medical, family, and psychosocial history including co‐morbidities, and relevant genetic information | 89 | 71 | 0.246 | ||
| 5d | Relevant past interventions and their outcomes | 96 | 75 | 0.075 | ||
| Clinical Findings | 6 | Describe the relevant physical examination (PE) findings | 100 | 100 | 84 |
|
| Timeline | 7 | Depict important milestones related to your diagnoses and interventions (table or figure) | 30 | 30 | 75 | 0.104 |
| Diagnostic Assessment | 8a | Diagnostic methods (such as PE, laboratory testing, imaging, questionnaires) | 74 | 100 | 96 |
|
| 8b | Diagnostic challenges (such as financial, language, or cultural) | 68 | 68 | 0.369 | ||
| 8c | Diagnostic reasoning including other diagnoses considered | 81 | 62 | 0.201 | ||
| 8d | Prognostic characteristics (such as staging in oncology) where applicable | 52 | 64 | 0.197 | ||
| Therapeutic Intervention | 9a | Types of intervention (such as pharmacologic, surgical, preventive, self‐care) | 96 | 100 | 90 |
|
| 9b | Administration of intervention (such as dosage, strength, duration) | 91 | 61 | 0.032 | ||
| 9c | Changes in intervention (with rationale) | 96 | 70 | 0.008 | ||
| Follow‐up and Outcomes | 10a | Clinician‐assessed outcomes and when appropriate patient‐assessed outcomes | 90 | 100 | 84 |
|
| 10b | Important follow‐up test results | 96 | 71 | 0.022 | ||
| 10c | Intervention adherence and tolerability (How was this assessed?) | 76 | 54 | 0.067 | ||
| 10d | Adverse and unanticipated events | 84 | 57 | 0.081 | ||
| Discussion | 11a | Discussion of the strengths and limitations in the management of this case | 88 | 71 | 68 | 0.365 |
| 11b | Discussion of the relevant medical literature | 98 | 89 | 0.179 | ||
| 11c | The rationale for conclusions (including assessment of possible causes) | 96 | 76 | 0.089 | ||
| 11d | The main “take‐away” lessons of this case report | 80 | 87 | 0.664 | ||
| Patient Perspective | 12 | Did the patient share his or her perspective or experience? (Include when appropriate) | 17 | 17 | 83 |
|
| Informed Consent | 13 | Did the patient give informed consent? Please provide if requested | 84 | 84 | 89 | 0.683 |
| Additional Information | 14 | Acknowledgement section; Competing Interests; IRB approval when required | 96 | 96 | 89 | 0.334 |
Kappa coefficient not quantifiable (two cells with zero).
Kappa coefficient not quantifiable (one cell with zero).
Figure 1Distribution of completeness of reporting (COR) scores of the CARE statement in included case reports stratified by journal of publication. Data presented as n, median [IQR]
Figure 2Completeness of reporting (COR) score of the included case reports detailed by items of CARE statement